Saturday 17 October 2026 Export IRMD’s income statement to Excel — free account

iRadimed Corporation

iRadimed Corporation’s revenue for fiscal 2025 (year ended December 2025) was $83.8 million, up 14.4% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS fell 8.89% and free cash flow grew 11.7%, each against the same quarter a year earlier. Revenue growth for five consecutive years.

88.27 1.10 −1.23%

Follow IRMD

Alert me

Market cap: $1.1B
P/E: 48.5×
Fwd P/E: 48.7×
Dividend yield: 0.87%
F-score: 6/9
Altman Z: 55.62
Beneish M: −2.55
Dividend safety: 40/100

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 18.86

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	6	7	4	1	5	4	4	2	—	—	1	—

Insider Ownership 34.84%

Capital & Financial Ratios $m

Market Cap 1,140.00

Revenue 86.34

Net Income 23.06

Free Cash Flow 24.55

Net Debt (59.08)

Current Ratio 9.46

Debt/Equity 0.00

P/E ratio 48.50

Fwd P/E 48.70

P/S ratio 13.07

P/B ratio 11.09

Past 5Y EPS Growth 73.91%

This Y EPS Growth 9.50%

Next Y EPS Growth 16.09%

Next Y revenue growth 9.85%

Next 5Y EPS Growth 12.05%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 66.83%

10-year low 10-year high

P/S against its own 10 years 90.34%

10-year low 10-year high

P/B against its own 10 years 93.29%

10-year low 10-year high

EV/Sales against its own 10 years 91.15%

10-year low 10-year high

EV/FCF against its own 10 years 56.14%

10-year low 10-year high

Dividends

Payout Ratio 0.43

Annual Dividend Rate 0.77

Annual Dividend Yield 0.87%

	total	individual payouts
2026	0.60	0.20 0.20 0.20
2025	0.68	0.17 0.17 0.17 0.17 0.50
2024	0.45	0.15 0.15 0.15
2023	0.15	1.05 0.15
2022	0.00	1.00
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	50	52	51	59
Receivables	12	11	14	13
Inventory	13	10	12	12
Other	—	—	—	—
	76	75	81	87

	2023	2024	2025	Q'26
Payables	2	2	2	2
ST’ Debt	—	—	—	—
Other	0	1	0	0
	16	9	10	9

Compound Annual Growth %

	10y	5y	3y
Sales	10.25%	21.45%	16.28%
Cash Flow	12.55%	33.80%	35.43%
Earnings	11.56%	75.02%	20.56%
Book Value	11.47%	9.04%	8.70%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	22	20	—	—	—
’25	20	20	21	23	84
’24	18	18	18	19	73
’23	15	16	17	17	66
’22	12	13	13	15	53
’21	9	10	11	12	42
’20	9	7	8	9	32

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	8	6	—	—	—
’25	4	8	7	6	25
’24	4	7	9	6	26
’23	5	4	1	4	13
’22	1	2	4	3	10
’21	1	4	3	3	11
’20	1	1	1	2	6

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	8	5	—	—	—
’25	0	5	6	6	17
’24	3	5	5	3	17
’23	(2)	3	1	3	5
’22	1	1	3	3	8
’21	1	3	3	3	11
’20	1	1	1	2	5

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	0.45	0.41	—	—	—
’25	0.37	0.45	0.43	0.50	1.75
’24	0.32	0.38	0.40	0.40	1.50
’23	0.27	0.33	0.40	0.36	1.35
’22	0.20	0.26	0.27	0.29	1.02
’21	0.11	0.12	0.20	0.31	0.74
’20	0.14	(0.17)	0.09	0.05	0.11

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	8.95	7.85	12.51	16.68	14.42	21.65	26.00	27.87	40.18	47.48	Analyst estimates 2026–2028 Powerpack
	High	28.00	15.75	38.78	29.80	28.43	48.75	55.92	51.04	57.95	98.53
People
People	Employees	80	83	95	114	110	110	123	148	160	166
	Revenue/emp, $m	0.41	0.28	0.32	0.34	0.29	0.38	0.43	0.44	0.46	0.50
Income, $m
Income, $m	Revenue	32	23	30	39	32	42	53	66	73	84
	Gross margin, %	81.06	75.87	76.31	77.11	74.33	76.65	77.45	76.50	76.94	76.75
	EBT	11	1	6	9	(1)	10	16	22	24	28
	EBT margin, %	33.70	6.05	20.36	23.48	(1.94)	23.52	30.36	33.16	33.14	33.84
	Net income	7	0	6	10	1	9	13	17	19	22
	Depreciation	1	1	1	1	1	1	1	1	1	1
Per share, $
Per share, $	Revenue	3.00	2.17	2.83	3.41	2.62	3.39	4.24	5.20	5.78	6.59
	Earnings	0.67	0.05	0.59	0.85	0.11	0.76	1.02	1.36	1.52	1.77
	Cash flow	0.87	0.32	0.69	0.91	0.48	0.91	0.80	1.07	2.02	1.96
	Capex	(0.14)	(0.08)	(0.02)	(0.04)	(0.05)	(0.06)	(0.15)	(0.64)	(0.70)	(0.66)
	Free cash flow	0.73	0.24	0.66	0.86	0.43	0.85	0.65	0.43	1.33	1.30
	Book value	2.95	3.10	3.90	4.92	5.06	5.85	5.86	5.67	6.85	7.44
	Shares, m	11	11	11	11	12	12	13	13	13	13
Valuation, ×
Valuation, ×	P/E	16.47	306.00	41.46	27.19	190.00	61.61	27.92	34.77	35.95	54.96
	P/S	3.73	7.05	8.65	6.85	8.72	13.64	6.71	9.09	9.51	14.77
	P/B	3.80	4.94	6.27	4.75	4.50	7.90	4.86	8.34	8.03	13.08
	EV/Sales	2.94	5.91	7.52	5.65	7.08	12.15	5.63	8.33	8.80	14.16
	EV/FCF	13.38	53.67	32.34	22.59	45.01	49.53	42.14	121.76	40.71	76.28
Cash, $m
Cash, $m	Operating cash flow	9	3	7	10	6	11	10	13	26	25
	Capex	(2)	(1)	0	0	(1)	(1)	(2)	(8)	(9)	(8)
	Free cash flow	8	3	7	10	5	11	8	5	17	17
Balance, $m
Balance, $m	Working capital	30	31	40	53	59	69	69	60	67	71
	Total debt	—	—	—	3	3	2	2	—	—	—
	Net debt	(26)	(26)	(34)	(46)	(52)	(63)	(58)	(50)	(52)	(51)
	Shareholders’ equity	32	33	42	56	61	72	74	71	87	95
Returns, %
Returns, %	ROA	19.92	1.31	14.42	16.72	1.99	12.12	15.24	19.35	20.20	21.71
	ROIC	109.91	12.19	49.58	58.28	(5.02)	63.44	62.16	57.82	39.69	37.60
	ROE	22.61	1.54	16.84	19.76	2.34	13.96	17.59	23.70	24.31	24.78

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
BVS Bioventus Inc.	$1.2B	16.4×	21.4×	+3.76% (above 0%: growing)	+345.45% (above 0%: growing)	−25.11% (below 0%: shrinking)	68.97%	12.48%	Compare
TNDM Tandem Diabetes Care, Inc.	$1.2B	— (loss-making)	— (loss-making)	+5.77% (above 0%: growing)	n/m	−146.34% (below 0%: shrinking)	56.87%	(5.42%)	Compare
IRMD iRadimed Corporation	$1.1B	48.5×	48.7×	+0.28% (above 0%: growing)	−8.89% (below 0%: shrinking)	+11.66% (above 0%: growing)	74.07%	31.23%
ENOV Enovis Corporation	$1.1B	— (loss-making)	195×	+3.23% (above 0%: growing)	n/m	+815.79% (above 0%: growing)	61.64%	2.99%	Compare
AORT Artivion, Inc.	$1.1B	— (loss-making)	142×	+11.32% (above 0%: growing)	n/m	−202.47% (below 0%: shrinking)	64.03%	(6.65%)	Compare
CBLL CeriBell, Inc.	$1.1B	— (loss-making)	— (loss-making)	+32.54% (above 0%: growing)	n/m	−68.63% (below 0%: shrinking)	92.32%	(71.11%)	Compare
IART Integra LifeSciences Holdings Corporation	$1.1B	— (loss-making)	26.1×	+0.76% (above 0%: growing)	n/m	+193.48% (above 0%: growing)	52.47%	4.61%	Compare
LMRI Lumexa Imaging Holdings, Inc.	$1.0B	— (loss-making)	14.2×	+7.82% (above 0%: growing)	n/m	+257.54% (above 0%: growing)	14.72%	8.72%	Compare
PRCT PROCEPT BioRobotics Corporation	$1.0B	— (loss-making)	— (loss-making)	+19.34% (above 0%: growing)	n/m	−24.43% (below 0%: shrinking)	66.01%	(28.98%)	Compare
Median of peers	$1.1B	—	26.1×	+6.80%	—	−24.77%	62.84%	(1.21%)

All 149 Medical Devices stocks →

iRadimed Corporation (IRMD) key facts

Strength: iRadimed Corporation’s revenue for fiscal 2025 (year ended December 2025) was $83.8 million, up 14.4% from fiscal 2024.
Strength: Net income was $22.5 million, or $1.77 per share (basic), a net margin of 26.8%.
iRadimed Corporation (IRMD) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, IRMD traded at $88.27, a market capitalization of $1.1 billion.
At that price the stock trades at 48.5× trailing-twelve-month earnings and 13.1× sales; its P/E is higher than 67% of its own readings over the past ten years.
iRadimed Corporation pays an annual dividend of $0.77 per share, a yield of 0.87%, with a payout ratio of 43.0%.
Return on equity was 24.8% and debt-to-equity 0.00.
Its Piotroski F-score is 6 out of 9 and its Altman Z-score is 55.62 (safe zone) for fiscal 2025.